First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold | Zendy

John A. Ormiston | Zendy; Patrick W. Serruys | Zendy; Yoshinobu Onuma | Zendy; RobertJan van Geuns | Zendy; Bernard De Bruyne | Zendy; Dariusz Dudek | Zendy; Leif Thuesen | Zendy; Pieter C. Smits | Zendy; Bernard Chevalier | Zendy; Dougal McClean | Zendy; Jacques Koolen | Zendy; Stephan Windecker | Zendy; Robert Whitbourn | Zendy; Ian T. Meredith | Zendy; Cécile Dorange | Zendy; Susan Veldhof | Zendy; Karine Miquel Hebert | Zendy; Richard Rapoza | Zendy; Héctor M. GarcíaGarcía | Zendy

Open Access

First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold

Author(s) -

John A. Ormiston,

Patrick W. Serruys,

Yoshinobu Onuma,

RobertJan van Geuns,

Bernard De Bruyne,

Dariusz Dudek,

Leif Thuesen,

Pieter C. Smits,

Bernard Chevalier,

Dougal McClean,

Jacques Koolen,

Stephan Windecker,

Robert Whitbourn,

Ian T. Meredith,

Cécile Dorange,

Susan Veldhof,

Karine Miquel Hebert,

Richard Rapoza,

Héctor M. GarcíaGarcía

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.112.971549

Subject(s) - medicine , intravascular ultrasound , optical coherence tomography , neointima , everolimus , bioresorbable scaffold , restenosis , radiology , clinical endpoint , stent , percutaneous coronary intervention , cardiology , clinical trial , myocardial infarction

Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research